Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
33.4M
-
Shares change
-
+15.9M
-
Total reported value, excl. options
-
$115M
-
Value change
-
+$54.7M
-
Put/Call ratio
-
3.55
-
Number of buys
-
22
-
Number of sells
-
-18
-
Price
-
$3.44
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q3 2016
58 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q3 2016.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.4M shares
of 193M outstanding shares and own 17.29% of the company stock.
Largest 10 shareholders include QVT Financial LP (16M shares), PRIMECAP MANAGEMENT CO/CA/ (3.87M shares), Falcon Edge Capital LP (2.62M shares), HealthCor Management, L.P. (2M shares), D. E. Shaw & Co., Inc. (1.72M shares), ARMISTICE CAPITAL, LLC (1.4M shares), SABBY MANAGEMENT, LLC (879K shares), BANK OF MONTREAL /CAN/ (862K shares), AXA (793K shares), and GOLDMAN SACHS GROUP INC (610K shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.